Introduction
============

Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer deaths worldwide [@b1]. Although lung cancer is mainly caused by tobacco use, genetic variations may determine individual outcome following exposure to tobacco carcinogens. Recently, genome-wide association studies (GWAS) have successfully identified dozens of loci that are associated with the risk of developing lung cancer [@b2]--[@b11]. However, these loci can only interpret a small fraction of familiar risk of lung cancer [@b12]. Because of the stringent screening criteria of GWAS, some potential causal variants and genes associated with lung cancer may be ignored. Thus, additional efforts on candidate genes that play important roles in lung carcinogenesis may be useful to uncover the missing heritability of lung cancer.

P21-activated kinase 1(PAK1) was initially identified as a downstream effector of the GTPases, Rac and Cdc42. Subsequent studies uncovered a variety of new functions for this kinase in growth factor and steroid receptor signaling, cytoskeleton remodeling, cell survival, oncogenic transformation, and gene transcription [@b13]. In addition, *PAK1* was found to function in the regulation of cell morphogenesis, motility, mitosis, angiogenesis [@b14]. Of interest, *PAK1* was frequently implicated in the tumorigenesis [@b15],[@b16] and up-regulation of *PAK1* was frequently detected in various human cancers including lung cancer [@b16]--[@b19]. Notably, PAK1 kinase can promote lung cancer cell motility, tumor migration, and invasion through activation of PAK1/LIMK1/cofilin pathway and CRK-II serine phosphorylation [@b20],[@b21]. These evidence collectively revealed the importance of *PAK1* in carcinogenesis, especially lung cancer.

Recently, two studies have demonstrated the associations between polymorphisms in *PAK1* gene and risk of papillary thyroid cancer and esophageal squamous cell carcinoma [@b22],[@b23]. However, the role of genetic variants in *PAK1* on the development of lung cancer is still unclear. In order to investigate whether genetic variants in *PAK1* contribute to susceptibility of developing lung cancer, we screened four potentially functional polymorphisms in *PAK1* gene and performed a genetic association analysis in a Chinese case**--**control study including 1341 lung cancer cases and 1982 cancer-free controls.

Materials and Methods
=====================

Study subjects
--------------

This case**--**control study was approved by the institutional review board of Nanjing Medical University. In total, 1341 lung cancer cases and 1982 controls were included. Patients with lung cancer were newly diagnosed and were consecutively recruited from the First Affiliated Hospital of Nanjing Medical University and the Cancer Hospital of Jiangsu Province since 2003. The histology for each case was histopathologically or cytologically confirmed by at least two local pathologists. Those who had a history of any cancer, metastasized cancer from other organs or had undergone radiotherapy or chemotherapy were excluded. Controls were selected from individuals participating screening of noncommunicable diseases in Jiangsu province. A total of 1982 controls were frequency-matched to lung cancer cases on age and gender. All of the subjects were genetically unrelated Han Chinese descent.

All participants signed the informed consent before taking part in this study. Each subject was face-to-face interviewed by trained interviewers to collect personal information on demographics data, cigarette smoking, and others. After the interview, approximately 5-mL venous blood was collected from each subject. Individuals were defined as smokers if they had smoked at an average of one cigarette or more per day and for at least 1 year in their lifetime; otherwise, subjects were considered as nonsmokers. Pack-years of smoking were defined as packs per day multiply smoking duration years. Smokers were divided into light and heavy smokers according to the threshold of 25 pack-years. The distribution of characteristics are summarized in [Table S1](#sd1){ref-type="supplementary-material"}. The age and gender between cases and controls were comparable. Compared to controls, cases had a higher rate of smoking (61.08% vs. 48.54%) and heavy smokers (42.28% vs. 24.07%). Among case group, 481 subjects (35.87%) were diagnosed with squamous cell carcinoma and the others were diagnosed with adenocarcinoma.

Potentially functional polymorphisms selection
----------------------------------------------

Based on the NCBI database and HapMap single nucleotide polymorphism (SNP) database, common SNPs (minor allele frequency, MAF ≥ 5%) in Chinese Han population were screened in gene regions (including 10-kb up-stream region of *PAK1*). After functional prediction by using SNPinfo Web Server (<http://snpinfo.niehs.nih.gov/>), a total of seven potentially functional SNPs were selected ([Table S2](#sd1){ref-type="supplementary-material"}). SNPs with low linkage disequilibrium analysis (*r*^2^ \< 0.8) were retained. As a result, four functional SNPs (rs2154754, rs3015993, rs7109645, and rs2844337) were selected to be genotyped ([Table S3](#sd1){ref-type="supplementary-material"}).

Genotyping
----------

Genomic DNA was isolated from leukocyte pellets of venous blood by proteinase K digestion and followed by phenolchloroform extraction and ethanol precipitation. The genotyping was performed by using Illumina Infinium® BeadChip (Illumina Inc, San Diego, CA, USA) and the genotype calling was performed using the GenTrain version 1.0 clustering algorithm in GenomeStudio V2011.1 (Illumina). Technicians who undertook the genotyping assays were blinded to the subjects' case or control status. Overall call rates of the 4 SNPs were from 99.64% to 100% ([Table S3](#sd1){ref-type="supplementary-material"}).

Statistical analysis
--------------------

The *χ*^2^ test for categorical variables and Student's *t*-tests for continuous variables were used to analyze distribution differences of demographic characteristics and genotypes between cases and controls. Hardy**--**Weinberg equilibrium for the distribution of each SNP was evaluated using the goodness-of-fit χ^2^ test by comparing the observed genotype frequencies with the expected ones among the controls. Odd ratios (ORs) and their 95% confidence intervals (CI) were calculated by using logistic regression analyses to evaluate the association between SNPs and lung cancer risk with an adjustment for age, gender and pack-years of smoking. To examine the differences between subgroups, the *χ*^2^- based *Q*-test was used to test the heterogeneity of effect sizes (ORs and 95% CIs) derived from corresponding subgroups. Multiplicative interactions were tested using a general logistic regression model by applying the equation: where *Y* is the logit of case-control status, *G* is SNP and *E* is environmental factor: pack year, ~β0~ is constant, *β*~*G*~ and β~*E*~ are the main effects of factors *G* and *E*, respectively, *β*~*GE*~ is the interaction term, Covar~*i*~ are the covariates for adjustment, including age and gender. All of the statistical analyses were performed using R software (version 2.15.3; The R Foundation for Statistical Computing, <http://www.cran.r-project.org/>) and Stata Version 10.0 software (Stata, College Station, TX).

Results
=======

The observed genotype frequencies for the four genotyped SNPs were all in agreement with Hardy**--**Weinberg equilibrium in the controls (*P *\> 0.05) ([Table S3](#sd1){ref-type="supplementary-material"}). Logistic regression analyses revealed that the A allele of rs2154754 was significantly associated with decreased risk of lung cancer (OR = 0.85, 95% CI: 0.77--0.95, *P = *0.004) (Table[1](#tbl1){ref-type="table"}). In addition, the T allele of rs3015993 was marginally associated with decreased risk of lung cancer (OR = 0.90, 95% CI: 0.81--1.00, *P *= 0.044). After multiple comparisons, rs2154754 was still significantly associated with the lung cancer risk (*P *\< 0.0125 for Bonferroni correction).However, there was no obvious evidence for the associations between the remaining 2 SNPs (rs7109645 and rs2844337) and lung cancer risk.

###### 

Associations between potentially functional SNPs in *PAK1* gene and lung cancer risk

  Genotype                                          Case*N* (%)   Control*N* (%)   OR (95% CI)[2](#tf1-2){ref-type="table-fn"}   *P* [2](#tf1-2){ref-type="table-fn"}
  ------------------------------------------------- ------------- ---------------- --------------------------------------------- --------------------------------------
  rs2154754(G\>A)[1](#tf1-1){ref-type="table-fn"}                                                                                
   GG                                               679 (50.63)   920 (46.42)      1                                             
   GA                                               545 (40.64)   837 (42.23)      0.89 (0.77--1.04)                             0.142
   AA                                               117 (8.73)    225 (11.35)      0.69 (0.54--0.89)                             0.004
   Additive model                                                                  0.85 (0.77--0.95)                             0.004
  rs3015993(A\>T)[1](#tf1-1){ref-type="table-fn"}                                                                                
   AA                                               361 (26.92)   479 (24.17)      1                                             
   AT                                               672 (50.11)   1011 (51.01)     0.87 (0.73--1.03)                             0.106
   TT                                               308 (22.97)   492 (24.82)      0.81 (0.66--1.00)                             0.046
   Additive model                                                                  0.90 (0.81--1.00)                             0.044
  rs7109645(A\>C)[1](#tf1-1){ref-type="table-fn"}                                                                                
   AA                                               842 (62.79)   1306 (65.89)     1                                             
   AC                                               445 (33.18)   603 (30.42)      1.13 (0.96--1.31)                             0.132
   CC                                               54 (4.03)     73 (3.69)        1.08 (0.74--1.56)                             0.700
   Additive model                                                                  1.09 (0.96--1.24)                             0.182
  rs2844337(A\>C)[1](#tf1-1){ref-type="table-fn"}                                                                                
   AA                                               832 (62.28)   1274 (64.51)     1                                             
   AC                                               453 (33.91)   629 (31.85)      1.08 (0.92--1.26)                             0.345
   CC                                               51 (3.81)     72 (3.64)        1.06 (0.73--1.55)                             0.747
   Additive model                                                                  1.06 (0.93--1.20)                             0.373

Major allele \> Minor allele.

Logistic regression with adjustment for age, gender, and pack-years of smoking.

Furthermore, in the stratification analysis, the association between rs2154754, rs3015993, and lung cancer risk were evaluated in subgroups based on age, gender, smoking status, pack-years of smoking, and histology type of lung cancer. As shown in Table[2](#tbl2){ref-type="table"}, there were no significant differences between subgroups for the association of the two SNPs with lung cancer risk. Interestingly, stronger effects of these two SNPs were observed among smokers (rs2154754: OR = 0.75, 95% CI: 0.64--0.88, *P *\< 0.001; and rs3015993: OR = 0.80, 95% CI: 0.69--0.93, *P *= 0.004) and heavy smokers (rs2154754: OR = 0.79, 95% CI: 0.66--0.95, *P *= 0.011; and rs3015993: OR = 0.83, 95% CI: 0.70--0.99, *P *= 0.040).

###### 

Stratified analysis on the associations of rs2154754 and rs3015993 in *PAK1* with lung cancer risk

  Characteristics            rs2154754(G\>A)   *P* ~*het*~ [3](#tf2-3){ref-type="table-fn"}   rs3015993(A\>T)     *P* ~*het*~ [3](#tf2-3){ref-type="table-fn"}                                                                                
  -------------------------- ----------------- ---------------------------------------------- ------------------- ---------------------------------------------- ------------- -------------- ------------------- ------------------- ------- -------
  Age                                                                                                                                                                                                                                         
   ≤60                       307/241/48        404/377/102                                    0.80 (0.68--0.95)   0.008                                          0.342         176/296/124    213/444/226         0.81 (0.70--0.95)   0.008   0.067
   \>60                      372/304/69        516/460/123                                    0.89 (0.77--1.03)   0.114                                          185/376/184   266/567/266    0.97 (0.85--1.12)   0.710                       
  Gender                                                                                                                                                                                                                                      
   Male                      507/358/84        621/588/149                                    0.79 (0.69--0.90)   0.001                                          0.076         257/479/213    321/698/339         0.87 (0.76--0.98)   0.022   0.387
   Female                    172/187/33        299/249/76                                     0.98 (0.81--1.20)   0.857                                          104/193/95    158/313/153    0.96 (0.80--1.16)   0.675                       
  Smoking status                                                                                                                                                                                                                              
   Current                   341/241/52        399/376/101                                    0.75 (0.64--0.88)   \<0.001                                        0.091         165/339/130    192/459/225         0.80 (0.69--0.93)   0.004   0.181
   Former                    94/72/19          46/31/9                                        1.03 (0.70--1.52)   0.881                                          50/84/51      22/44/20       1.02 (0.71--1.46)   0.917                       
   Never                     244/232/46        475/430/115                                    0.94 (0.79--1.10)   0.425                                          146/249/127   265/508/247    0.96 (0.83--1.12)   0.630                       
  Pack-years                                                                                                                                                                                                                                  
   0                         244/232/46        475/430/115                                    0.94 (0.79--1.10)   0.425                                          0.321         146/249/127    265/508/247         0.96 (0.83--1.12)   0.630   0.404
   0--25                     129/104/19        226/204/55                                     0.80 (0.63--1.02)   0.066                                          64/136/52     108/261/116    0.84 (0.66--1.05)   0.129                       
   \>25                      306/209/52        219/203/55                                     0.79 (0.66--0.95)   0.011                                          151/287/129   106/242/129    0.83 (0.70--0.99)   0.040                       
  Histology type                                                                                                                                                                                                                              
   Squamous cell carcinoma   245/193/43        920/837/225                                    0.86 (0.73--1.01)   0.074                                          0.913         134/236/111    479/1011/492        0.88 (0.75--1.03)   0.109   0.737
   Adenocarcinoma            434/352/74        920/837/225                                    0.85 (0.75--0.96)   0.009                                          227/436/197   479/1011/492   0.91 (0.81--1.03)   0.131                       

Wild-type homozygote/heterozygote/variant homozygote.

Adjusted for age, gender, and pack-years of smoking where appropriate in additive model.

*P* for heterogeneity.

In order to investigate whether the effect of the identified variants on lung cancer was modified by cigarette smoking, we performed interaction analysis between the two SNPs and smoking levels. We identified a significant multiplicative interaction between rs2154754 and smoking levels on lung cancer risk (*P* for multiplicative interaction = 0.042) (Table[3](#tbl3){ref-type="table"}). However, no significant multiplicative interaction was observed between rs3015993 and pack-years of smoking on lung cancer risk (data not shown).

###### 

The interaction between rs2154754 genotypes and smoking levels on lung cancer risk

  Smoking levels                       Genotype   Case*N* (%)   Control*N* (%)   OR (95% CI)         *P* [1](#tf3-1){ref-type="table-fn"}
  ------------------------------------ ---------- ------------- ---------------- ------------------- --------------------------------------
  0                                    GA/AA      278 (20.73)   545 (27.50)      1                   
  0                                    GG         244 (18.20)   475 (23.97)      1.01 (0.81--1.24)   0.973
  0--25                                GA/AA      123 (9.17)    259 (13.07)      1.17 (0.88--1.57)   0.282
  0--25                                GG         129 (9.62)    226 (11.40)      1.42 (1.06--1.91)   0.019
  \>25                                 GA/AA      261 (19.46)   258 (13.02)      2.68 (2.06--3.47)   \<0.001
  \>25                                 GG         306 (22.82)   219 (11.04)      3.71 (2.85--4.83)   \<0.001
  *P* for multiplicative interaction              0.042                                              

Adjusting for age and gender.

We also conducted a combined analysis to evaluate the cumulative effect of the two identified SNPs. As expect, we found a significant allele-dosage association between number of protective alleles and lung cancer risk (*P*~trend~ = 0.008). As shown in Table[4](#tbl4){ref-type="table"}, compared with individuals without protective alleles, those carrying "4" protective alleles had a 33% (OR = 0.67, 95% CI: 0.51--0.87, *P *= 0.003) reduced risk of developing lung cancer. These data indicated that individuals carrying more protective alleles had a lower risk of lung cancer.

###### 

Combined effects of rs2154754 and rs3015993 on lung cancer risk

  Number of protective alleles   Case*N* (%)   Control*N* (%)   OR (95% CI)         *P* [1](#tf4-1){ref-type="table-fn"}
  ------------------------------ ------------- ---------------- ------------------- --------------------------------------
  0                              361 (26.92)   479 (24.17)      1                   
  1                              272 (20.28)   378 (19.07)      0.92 (0.74--1.14)   0.459
  2                              446 (33.26)   696 (35.12)      0.84 (0.70--1.01)   0.071
  3                              145 (10.81)   204 (10.29)      0.94 (0.72--1.22)   0.648
  4                              117 (8.73)    225 (11.35)      0.67 (0.51--0.87)   0.003
  Trend                                                                             0.008

Derived from logistic regression with an adjustment for age, gender, and pack-years of smoking.

Discussion
==========

In our present study, we evaluated the association of four potentially functional polymorphisms in the *PAK1* with lung cancer risk in a case**--**control study including 1341 cases and 1982 controls in a Chinese population. Two SNPs (rs2154754 and rs3015993) were identified to be significantly associated with lung cancer risk. The SNP rs2154754 was detected with an approximately 15% decreased risk and rs3015993 was detected with 10% decreased risk of lung cancer risk in our population. The SNP rs2154754 kept significant after multiple comparisons. To the best of our knowledge, this is the first association study of polymorphisms in *PAK1* and lung cancer.

The *PAK1* gene is located on 11q13-q14 and this region is frequently amplified in many human cancers, with a complex structure harboring multiple potential oncogenic drivers [@b22],[@b24]. Emerging evidences have suggested that *PAK1* plays an important role in carcinogenesis and tumor progression [@b13],[@b14]. In special, for lung cancer *PAK1* could promote cell motility, tumor migration, and invasion through different mechanism [@b20],[@b21]. Our current study provided genetic evidence at the population level that *PAK1* may be involved in the carcinogenesis and development of lung cancer and further highlighted the important role of genetic variants in *PAK1* as molecular biomarkers for lung cancer susceptibility.

Before multiple comparisons, there were two positive SNPs (rs2154754 and rs3015993). The SNPs rs2154754 and rs3015993 are both located on 15th intron of *PAK1*. Recently, mutations in intron have been reported to lead to transcriptional dysregulation [@b25]. According to the web-based SNP analysis tool: SNPinfo, the base change for rs2154754 and rs3015993 may influence the binding of the transcription factors and then lead to transcriptional dysregulation of *PAK1*.We then performed functional annotation for the two SNPs, as well as those tagged by the two SNPs (*r*^2^ \> 0.8) based on DNase-seq database and RegulomeDB (<http://regulome.stanford.edu/>) ([Table S4](#sd1){ref-type="supplementary-material"}) [@b26]. Among the two identified SNPs and those 77 highly correlated SNPs, seven SNPs are within open chromatin regions associated with gene regulatory elements. Furthermore, 10 SNPs located in motifs may influence the binding of specified transcription factors. These suggest that the 2 marker SNPs and those tagged by which may transcriptionally modulate the expression of *PAK1* gene. It is plausible that these variants may result in the aberrant activities of certain transcription factors. In turn, these factors interactively regulate the expression of the *PAK1* gene, hence regulating lung carcinogenesis through different mechanisms. However, no experimental evidence validates this hypothesis and future functional studies are warranted to clarify this point.

Notably, we found that the effect of rs2154754 mainly restricted on current smokers, especially on heavy smokers. The genotypes of rs2154754 showed significant interaction with smoking levels on lung cancer risk. Zhang et al. [@b27] reported that cigarette exposure could activate the phosphatidylinositol 3-kinase (PI3K)-Akt pathway and the proto-oncogene *FRA-1*, which is known to up-regulate the expression of genes involved in tumor progression and invasion. They also found that the PI3K through *PAK1* regulates *FRA-1* proto-oncogene induction by cigarette smoke and the subsequent activation of the Elk1 and cAMP-response element-binding protein transcription factors. This finding can partly interpret our interaction outcome. It is plausible that variant genotypes of rs2154754 may regulate the expression of the *PAK1* gene and then regulate the cigarette smoke-induced *FRA-1* proto-oncogene expression, subsequently altering the role of *FRA-1* on up-regulating the expression of genes involved in tumor progression and invasion. However, this hypothesis is very preliminary and merit further experimental investigation.

In summary, our study investigated the role of genetic variants in *PAK1* gene in lung cancer development in a Chinese population. Our results suggested, for the first time, that genetic variants in *PAK1* may modify the risk of lung cancer. Further independent studies incorporating functional evaluations are warranted to validate the association and clarify the biological mechanisms of these SNPs in lung cancer development.
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